{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T23:13:51Z","timestamp":1792192431929,"version":"4.4.0"},"reference-count":36,"publisher":"American Society of Hematology","issue":"18","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2019,10,31]]},"abstract":"<jats:p>Yacoub et al report excellent responses to pegylated interferon alfa-2a in patients with hydroxyurea-resistant\/intolerant polycythemia vera or essential thrombocythemia.<\/jats:p>","DOI":"10.1182\/blood.2019000428","type":"journal-article","created":{"date-parts":[[2019,9,13]],"date-time":"2019-09-13T00:45:12Z","timestamp":1568335512000},"page":"1498-1509","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":173,"title":["Pegylated interferon alfa-2a for polycythemia vera or essential thrombocythemia resistant or intolerant to hydroxyurea"],"prefix":"10.1182","volume":"134","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5293-4620","authenticated-orcid":false,"given":"Abdulraheem","family":"Yacoub","sequence":"first","affiliation":[{"name":"Division of Hematologic Malignancies and Cellular Therapeutics, The University of Kansas Cancer Center, Westwood, KS;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8400-0483","authenticated-orcid":false,"given":"John","family":"Mascarenhas","sequence":"additional","affiliation":[{"name":"Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heidi","family":"Kosiorek","sequence":"additional","affiliation":[{"name":"Mayo Clinic, Scottsdale, AZ;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8019-2940","authenticated-orcid":false,"given":"Josef T.","family":"Prchal","sequence":"additional","affiliation":[{"name":"Division of Hematology, University of Utah School of Medicine and"},{"name":"Huntsman Cancer Center, Salt Lake City, UT;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dmitry","family":"Berenzon","sequence":"additional","affiliation":[{"name":"Comprehensive Cancer Center, Wake Forest University Medical Center, Wake Forest Health, Winston-Salem, NC;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria R.","family":"Baer","sequence":"additional","affiliation":[{"name":"Greenebaum Comprehensive Cancer Center, University of Maryland, Baltimore, MD;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8150-5542","authenticated-orcid":false,"given":"Ellen","family":"Ritchie","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Medicine, Richard T. Silver Myeloproliferative Neoplasms Center, Weill Cornell Medical College, New York, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard T.","family":"Silver","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Medicine, Richard T. Silver Myeloproliferative Neoplasms Center, Weill Cornell Medical College, New York, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig","family":"Kessler","sequence":"additional","affiliation":[{"name":"Georgetown University Medical Center, Washington, DC;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elliott","family":"Winton","sequence":"additional","affiliation":[{"name":"Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Chiara","family":"Finazzi","sequence":"additional","affiliation":[{"name":"Department of Hematology, Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII, Bergamo, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3739-7502","authenticated-orcid":false,"given":"Alessandro","family":"Rambaldi","sequence":"additional","affiliation":[{"name":"Department of Hematology, Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII, Bergamo, Italy;"},{"name":"Department of Oncology, University of Milan, Ospedale Papa Giovanni XXIII, Bergamo, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro M.","family":"Vannucchi","sequence":"additional","affiliation":[{"name":"Center for Research and Innovation of Myeloproliferative Neoplasms, Azienda Ospedaliero-Universitaria Careggi, and"},{"name":"Denothe Excellence Center, University of Florence, Florence, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Leibowitz","sequence":"additional","affiliation":[{"name":"Department of Oncology, Palo Alto Medical Foundation, Sutter Health, Palo Alto, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damiano","family":"Rondelli","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, University of Illinois, Chicago, IL;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murat O.","family":"Arcasoy","sequence":"additional","affiliation":[{"name":"Division of Hematology, Duke University School of Medicine, Durham, NC;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosalind","family":"Catchatourian","sequence":"additional","affiliation":[{"name":"Department of Oncology, John H. Stroger Jr. Hospital of Cook County, Chicago, IL;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5796-0737","authenticated-orcid":false,"given":"Joseph","family":"Vadakara","sequence":"additional","affiliation":[{"name":"Geisinger Medical Center, Danville, PA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4195-2289","authenticated-orcid":false,"given":"Vittorio","family":"Rosti","sequence":"additional","affiliation":[{"name":"Laboratory of Biochemistry, Biotechnology, and Advanced Diagnosis, Center for the Study of Myelofibrosis, Istituto Di Ricovero e Cura a Carattere Scientifico, Foundation Policlinico San Matteo, Pavia, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1125-4060","authenticated-orcid":false,"given":"Elizabeth","family":"Hexner","sequence":"additional","affiliation":[{"name":"Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Kremyanskaya","sequence":"additional","affiliation":[{"name":"Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lonette","family":"Sandy","sequence":"additional","affiliation":[{"name":"Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3033-1081","authenticated-orcid":false,"given":"Joseph","family":"Tripodi","sequence":"additional","affiliation":[{"name":"Department of Pathology and"},{"name":"Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vesna","family":"Najfeld","sequence":"additional","affiliation":[{"name":"Department of Pathology and"},{"name":"Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noushin","family":"Farnoud","sequence":"additional","affiliation":[{"name":"Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elli","family":"Papaemmanuil","sequence":"additional","affiliation":[{"name":"Computational Oncology,"},{"name":"Center for Hematological Malignancies, and"},{"name":"Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Salama","sequence":"additional","affiliation":[{"name":"Mayo Clinic Laboratories, Rochester, MN;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rona","family":"Singer-Weinberg","sequence":"additional","affiliation":[{"name":"New York Blood Center, New York, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raajit","family":"Rampal","sequence":"additional","affiliation":[{"name":"Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith D.","family":"Goldberg","sequence":"additional","affiliation":[{"name":"Department of Population Health and"},{"name":"Department of Environmental Medicine, New York University School of Medicine, New York, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiziano","family":"Barbui","sequence":"additional","affiliation":[{"name":"Ospedali Riuniti, Bergamo, Italy; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruben","family":"Mesa","sequence":"additional","affiliation":[{"name":"UT Health San Antonio Cancer Center, San Antonio, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9912-1085","authenticated-orcid":false,"given":"Amylou C.","family":"Dueck","sequence":"additional","affiliation":[{"name":"Mayo Clinic, Scottsdale, AZ;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald","family":"Hoffman","sequence":"additional","affiliation":[{"name":"Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2019,9,12]]},"reference":[{"issue":"20","key":"2019111523401106200_B1","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"issue":"4","key":"2019111523401106200_B2","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1182\/blood.V6.4.372.372","article-title":"Some speculations on the myeloproliferative syndromes","volume":"6","author":"Dameshek","year":"1951","journal-title":"Blood"},{"issue":"10","key":"2019111523401106200_B3","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1200\/JCO.2005.07.062","article-title":"Vascular and neoplastic risk in a large cohort of patients with polycythemia vera","volume":"23","author":"Marchioli","year":"2005","journal-title":"J Clin Oncol"},{"issue":"6","key":"2019111523401106200_B4","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1182\/blood-2011-10-387787","article-title":"Assessment and prognostic value of the European LeukemiaNet criteria for clinicohematologic response, resistance, and intolerance to hydroxyurea in polycythemia vera","volume":"119","author":"Alvarez-Larr\u00e1n","year":"2012","journal-title":"Blood"},{"issue":"1","key":"2019111523401106200_B5","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/j.1365-2141.2010.08430.x","article-title":"Clinical evaluation of the European LeukaemiaNet criteria for clinicohaematological response and resistance\/intolerance to hydroxycarbamide in essential thrombocythaemia","volume":"152","author":"Hern\u00e1ndez-Boluda","year":"2011","journal-title":"Br J Haematol"},{"issue":"2","key":"2019111523401106200_B6","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1111\/j.1365-2141.1989.tb04251.x","article-title":"In vivo and in vitro inhibitory effect of alpha-interferon on megakaryocyte colony growth in essential thrombocythaemia","volume":"71","author":"Gugliotta","year":"1989","journal-title":"Br J Haematol"},{"issue":"3","key":"2019111523401106200_B7","doi-asserted-by":"crossref","first-page":"392","DOI":"10.2174\/138945011794815275","article-title":"Interferon-alpha in the treatment of Philadelphia-negative chronic myeloproliferative neoplasms. Status and perspectives","volume":"12","author":"Hasselbalch","year":"2011","journal-title":"Curr Drug Targets"},{"issue":"3","key":"2019111523401106200_B8","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/BF01697629","article-title":"Possible selective effects of interferon alpha-2b on a malignant clone in a case of polycythemia vera","volume":"66","author":"Hino","year":"1993","journal-title":"Ann Hematol"},{"issue":"5","key":"2019111523401106200_B9","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1111\/j.1600-0609.1993.tb00157.x","article-title":"The in vitro effects of interferon-gamma, interferon-alpha, and tumour-necrosis factor-alpha on erythroid burst-forming unit growth in patients with non-leukaemic myeloproliferative disorders","volume":"50","author":"Kanfer","year":"1993","journal-title":"Eur J Haematol"},{"issue":"4","key":"2019111523401106200_B10","doi-asserted-by":"crossref","first-page":"e165","DOI":"10.1016\/S2352-3026(17)30030-3","article-title":"Pegylated interferon alfa-2a in patients with essential thrombocythaemia or polycythaemia vera: a post-hoc, median 83 month follow-up of an open-label, phase 2 trial","volume":"4","author":"Masarova","year":"2017","journal-title":"Lancet Haematol"},{"issue":"2","key":"2019111523401106200_B11","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1002\/(SICI)1096-8652(199710)56:2<126::AID-AJH10>3.0.CO;2-A","article-title":"Polycythemia vera treated with recombinant interferon-alpha 2a: evidence of a selective effect on the malignant clone","volume":"56","author":"Massaro","year":"1997","journal-title":"Am J Hematol"},{"issue":"6","key":"2019111523401106200_B12","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1182\/blood-2012-07-442012","article-title":"Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon \u03b1-2a","volume":"122","author":"Quint\u00e1s-Cardama","year":"2013","journal-title":"Blood"},{"issue":"32","key":"2019111523401106200_B13","doi-asserted-by":"crossref","first-page":"5418","DOI":"10.1200\/JCO.2009.23.6075","article-title":"Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera","volume":"27","author":"Quint\u00e1s-Cardama","year":"2009","journal-title":"J Clin Oncol"},{"issue":"8607","key":"2019111523401106200_B14","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S0140-6736(88)92881-4","article-title":"Recombinant interferon-alpha for treatment of polycythaemia vera","volume":"332","author":"Silver","year":"1988","journal-title":"Lancet"},{"issue":"6","key":"2019111523401106200_B15","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1182\/blood-2006-03-009860","article-title":"High molecular response rate of polycythemia vera patients treated with pegylated interferon alpha-2a","volume":"108","author":"Kiladjian","year":"2006","journal-title":"Blood"},{"issue":"9","key":"2019111523401106200_B16","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1002\/cncr.23018","article-title":"PEG-IFN-\u03b1-2b therapy in BCR-ABL-negative myeloproliferative disorders: final result of a phase 2 study","volume":"110","author":"Jabbour","year":"2007","journal-title":"Cancer"},{"issue":"11","key":"2019111523401106200_B17","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1002\/cncr.21900","article-title":"A phase II trial of pegylated interferon \u03b1-2b therapy for polycythemia vera and essential thrombocythemia: feasibility, clinical and biologic effects, and impact on quality of life","volume":"106","author":"Samuelsson","year":"2006","journal-title":"Cancer"},{"issue":"22","key":"2019111523401106200_B18","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.475.475","article-title":"Final results from PROUD-PV a randomized controlled phase 3 trial comparing ropeginterferon alfa-2b to hydroxyurea in polycythemia vera patients [abstract]","volume":"128","author":"Gisslinger","year":"2016","journal-title":"Blood."},{"issue":"15","key":"2019111523401106200_B19","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1182\/blood-2015-04-637280","article-title":"Ropeginterferon alfa-2b, a novel IFN\u03b1-2b, induces high response rates with low toxicity in patients with polycythemia vera","volume":"126","author":"Gisslinger","year":"2015","journal-title":"Blood"},{"issue":"3","key":"2019111523401106200_B20","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1002\/cncr.22026","article-title":"Long-term effects of the treatment of polycythemia vera with recombinant interferon-alpha","volume":"107","author":"Silver","year":"2006","journal-title":"Cancer"},{"key":"2019111523401106200_B21","doi-asserted-by":"crossref","unstructured":"Mascarenhas\n              J\n            , KosiorekHE, PrchalJT,  Results of the Myeloproliferative Neoplasms - Research Consortium (MPN-RC) 112 randomized trial of pegylated interferon alfa-2a (PEG) versus hydroxyurea (HU) therapy for the treatment of high risk polycythemia vera (PV) and high risk essential thrombocythemia (ET) [abstract]. Blood. 2018;132(suppl 1). Abstract 577.","DOI":"10.1182\/blood-2018-99-111946"},{"issue":"19","key":"2019111523401106200_B22","doi-asserted-by":"crossref","first-page":"5019","DOI":"10.1182\/blood-2011-01-293050","article-title":"The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications","volume":"117","author":"Campo","year":"2011","journal-title":"Blood"},{"issue":"2","key":"2019111523401106200_B23","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/sj.leu.2404473","article-title":"A unified definition of clinical resistance\/intolerance to hydroxyurea in essential thrombocythemia: results of a consensus process by an international working group [published correction appears in Leukemia. 2007;21(5):1136]","volume":"21","author":"Barosi","year":"2007","journal-title":"Leukemia"},{"issue":"20","key":"2019111523401106200_B24","doi-asserted-by":"crossref","first-page":"4829","DOI":"10.1182\/blood-2008-09-176818","article-title":"Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference","volume":"113","author":"Barosi","year":"2009","journal-title":"Blood"},{"issue":"23","key":"2019111523401106200_B25","doi-asserted-by":"crossref","first-page":"4778","DOI":"10.1182\/blood-2013-01-478891","article-title":"Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project","volume":"121","author":"Barosi","year":"2013","journal-title":"Blood"},{"issue":"22","key":"2019111523401106200_B26","doi-asserted-by":"crossref","first-page":"3616","DOI":"10.1182\/blood-2013-08-518886","article-title":"Clinical and biological implications of driver mutations in myelodysplastic syndromes","volume":"122","author":"Papaemmanuil","year":"2013","journal-title":"Blood"},{"issue":"14","key":"2019111523401106200_B27","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1093\/bioinformatics\/bts280","article-title":"Exploring single-sample SNP and INDEL calling with whole-genome de novo assembly","volume":"28","author":"Li","year":"2012","journal-title":"Bioinformatics"},{"issue":"D1","key":"2019111523401106200_B28","doi-asserted-by":"crossref","first-page":"D777","DOI":"10.1093\/nar\/gkw1121","article-title":"COSMIC: somatic cancer genetics at high-resolution","volume":"45","author":"Forbes","year":"2017","journal-title":"Nucleic Acids Res"},{"issue":"7616","key":"2019111523401106200_B29","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1038\/nature19057","article-title":"Analysis of protein-coding genetic variation in 60,706 humans","volume":"536","author":"Lek","year":"2016","journal-title":"Nature"},{"issue":"7571","key":"2019111523401106200_B30","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/nature15393","article-title":"A global reference for human genetic variation","volume":"526","author":"Auton","year":"2015","journal-title":"Nature"},{"issue":"7571","key":"2019111523401106200_B31","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/nature15394","article-title":"An integrated map of structural variation in 2,504 human genomes","volume":"526","author":"Sudmant","year":"2015","journal-title":"Nature"},{"issue":"4","key":"2019111523401106200_B32","doi-asserted-by":"crossref","first-page":"e1004873","DOI":"10.1371\/journal.pcbi.1004873","article-title":"CNVkit: genome-wide copy number detection and visualization from targeted DNA sequencing","volume":"12","author":"Talevich","year":"2016","journal-title":"PLOS Comput Biol"},{"issue":"33","key":"2019111523401106200_B33","doi-asserted-by":"crossref","first-page":"4098","DOI":"10.1200\/JCO.2012.42.3863","article-title":"Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs [published correction appears in J Clin Oncol. 2012;30(36):4590]","volume":"30","author":"Emanuel","year":"2012","journal-title":"J Clin Oncol"},{"issue":"15","key":"2019111523401106200_B34","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1056\/NEJMoa1716614","article-title":"Classification and Personalized Prognosis in Myeloproliferative Neoplasms","volume":"379","author":"Grinfeld","year":"2018","journal-title":"N Engl J Med"},{"issue":"17","key":"2019111523401106200_B35","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1182\/blood-2017-05-785790","article-title":"Ruxolitinib vs best available therapy for ET intolerant or resistant to hydroxycarbamide","volume":"130","author":"Harrison","year":"2017","journal-title":"Blood"},{"issue":"5","key":"2019111523401106200_B36","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1056\/NEJMoa1409002","article-title":"Ruxolitinib versus standard therapy for the treatment of polycythemia vera","volume":"372","author":"Vannucchi","year":"2015","journal-title":"N Engl J Med"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/134\/18\/1498\/1504050\/bloodbld2019000428.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/134\/18\/1498\/1504050\/bloodbld2019000428.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,16]],"date-time":"2019-11-16T00:27:46Z","timestamp":1573864066000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/134\/18\/1498\/374977\/Pegylated-interferon-alfa2a-for-polycythemia-vera"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,12]]},"references-count":36,"journal-issue":{"issue":"18","published-online":{"date-parts":[[2019,9,12]]},"published-print":{"date-parts":[[2019,10,31]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2019000428","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,12]]}}}